Currently, the inhibitors of PD-1/PD-L1 either in monotherapy or combined with chemotherapy are approved in stage IV NSCLC as the first-line setting providing long-lasting responses and survival [46,47]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.